HOME >> BIOLOGY >> NEWS
Study identifies which patients can benefit from targeted lung cancer drug and why

.D., Ph.D., of Dana-Farber and Brigham and Women's Hospital, and Jeffrey Lee, of Dana-Farber and Harvard Medical School (HMS).

"Until now, there has not been a great deal that medicine could do for most patients with non-small cell lung cancer," says Meyerson, who is also on the faculty of the Broad Institute and HMS. "This study is the first indication that a therapy targeted for a specific group of patients can have an impact on this disease. It demonstrates how the growing understanding of human biology and the Human Genome Project are converging to produce an immediate effect on cancer care."

In the study, Dana-Farber and Broad investigators led by Meyerson and Sellers scanned non-small cell lung tumors from 58 Japanese and 61 American patients for gene mutations. While just one of the American patients had a mutation in the gene for EGFR (which stands for "epidermal growth factor receptor"), 15 of the Japanese patients did. The investigators knew from previous research that Iressa, an EGFR kinase blocker that has had only sporadic success against NSCLC, shrinks such tumors more frequently in Japanese patients than in Americans.

Meanwhile, study co-authors Johnson and Janne found that tumor tissue from a woman with cancer that had spread to the lining around her lungs a condition called adenocarcinoma was very responsive to gefitinib when tested in a laboratory dish. When the adenocarcinoma's DNA was analyzed, it was found to have the same EGFR gene mutation that Meyerson and Sellers' group had found.

"We were struck that certain groups of NSCLC patients appear to be more likely to have EGFR mutations than others," Johnson remarks. "Mutations were more frequent in women, in Japanese patients, and in patients with adenocarcinoma. These are the exact same groups that are most likely to experience tumor shrinkage when treated with gefitinib. Because Iressa is an EGFR inhibitor, we reasoned that patients with EGFR mutations migh
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
29-Apr-2004


Page: 1 2 3

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study of flu patients reveals virus outsmarting key drug
7. Study in Science reveals recreational fishing takes big bite of ocean catch
8. Study suggests cell-cycle triggers might be cancer drug targets
9. Study narrows search for genes placing men at increased risk for prostate cancer
10. Study links high carbohydrate diet to increased breast cancer risk
11. Study explains spatial orientation differences between sexes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/30/2020)... N.Y. (PRWEB) , ... April 28, 2020 , ... ... these webinars are Lachman Consultants latest effort in providing timely and critical information ... further complicated by social distancing and health safety concerns. , “Providing the most ...
(Date:4/26/2020)... ... April 23, 2020 , ... A team of researchers ... developing a synthetic antibody to SARS-CoV-2, the virus that causes coronavirus disease (COVID-19). This ... be another potential treatment option for COVID-19. , The efforts are being led by ...
(Date:4/22/2020)... (PRWEB) , ... April 21, 2020 , ... ... digital transformation and innovation in technology and compliance, announces a new managed service ... best-in-class trio of alliances – Box, ComplianceQuest, and USDM Life Sciences (USDM) – ...
Breaking Biology News(10 mins):
(Date:5/5/2020)... ... May 05, 2020 , ... ProductLife Group has marked ... Duburcq joins the group after 13 years at Altran, where he was Group VP ... in Immunology and being a Pharmacist, Xavier was involved in his early career in ...
(Date:5/1/2020)... ... 30, 2020 , ... The winners of Fast Company’s 2020 ... concepts that are actively engaged and deeply committed to changing the world. Amongst ... the top prize in the Experimental category. , The RASTRUM™ 3D Bioprinter from ...
(Date:4/23/2020)... NEWPORT NEWS, Va. (PRWEB) , ... April 22, ... ... shortage of essential equipment for healthcare providers to protect themselves from COVID-19. Virginia ... it requests from the Federal Emergency Management Association (FEMA). , As Governor Northam ...
(Date:4/22/2020)... (PRWEB) , ... April 21, 2020 , ... ... FXIII chromogenic method for determination of FXIII. , Aniara Diagnostica, a multi-national distributor ... commitment to meeting today’s highest standards for product quality and cost-efficient delivery. ...
Breaking Biology Technology:
Cached News: